{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-104.1","upperLimit":"0","value":"-0.61"},{"groupId":"OG001","lowerLimit":"-0.61","upperLimit":"0","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG003","lowerLimit":"-2436.1","upperLimit":"-2436.1","value":"-2436.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"End of Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-449.6","upperLimit":"-0.14","value":"-2.9"},{"groupId":"OG001","lowerLimit":"-1.9","upperLimit":"0","value":"-0.28"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG003","lowerLimit":"-1.92","upperLimit":"-1.92","value":"-1.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"At treatment discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.98","upperLimit":"0","value":"-1.55"},{"groupId":"OG001","lowerLimit":"-4.87","upperLimit":"4.07","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG003","lowerLimit":"-1.92","upperLimit":"-1.92","value":"-1.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"6-month follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-228.2","upperLimit":"-0.07","value":"-0.56"},{"groupId":"OG001","lowerLimit":"-4.75","upperLimit":"0","value":"-2.7"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG003","lowerLimit":"-1.15","upperLimit":"-1.15","value":"-1.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"12-month follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"description":"Differences from baseline (specified follow-up assessment minus baseline) in EBV viral load.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Arm A (VR-DA-EPOCH) at the recommended phase II dose of Vorinostat (300 mg once a day for days 1-5 of a cycle).","id":"OG000","title":"Phase II, VR-DA-EPOCH"},{"description":"Arm B (DA-R-EPOCH), which is the same treatment as Arm A, but without Vorinostat","id":"OG001","title":"Phase II, DA-R-EPOCH"},{"description":"Arm A (VR-DA-EPOCH) with Vorinostat at 300mg once a day on days 1-5 of a cycle (Phase I dose Level 1)","id":"OG002","title":"Phase I: VR-DA-EPOCH, Dose Level 1"},{"description":"Arm A (VR-DA-EPOCH) with Vorinostat at 400mg once a day on days 1-5 of a cycle (Phase I dose Level 1)","id":"OG003","title":"Phase I: VR-DA-EPOCH, Dose Level 2"},{"description":"Arm C (VR-CHOP) with Vorinostat at 300 mg once a day on days 1-5 of a cycle (Phase I Dose Level 1 for low risk participants). This arm was discontinued due to low accrual.","id":"OG004","title":"Phase I: VR-CHOP, Dose Level 1"}],"paramType":"MEDIAN","populationDescription":"Median Change from the baseline and IQR were calculated. The measurement unit is IU/mL.","reportingStatus":"POSTED","timeFrame":"Baseline up to 12 months","title":"Changes in Epstein-Barr Virus (EBV) Viral Load","type":"SECONDARY","unitOfMeasure":"IU/mL"}